A detailed history of Advisor Group Holdings, Inc. transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,349 shares of GOSS stock, worth $1,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,349
Previous 1,349 -0.0%
Holding current value
$1,335
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.51 - $1.27 $459 - $1,143
900 Added 200.45%
1,349 $1,000
Q1 2024

May 10, 2024

BUY
$0.8 - $1.51 $43 - $81
54 Added 13.67%
449 $0
Q4 2023

Feb 12, 2024

SELL
$0.48 - $1.08 $98 - $221
-205 Reduced 34.17%
395 $0
Q3 2023

Nov 13, 2023

BUY
$0.78 - $1.82 $234 - $546
300 Added 100.0%
600 $0
Q2 2023

Aug 10, 2023

SELL
$0.98 - $1.53 $543 - $849
-555 Reduced 64.91%
300 $0
Q1 2023

May 12, 2023

BUY
$0.96 - $2.92 $181 - $551
189 Added 28.38%
855 $1,000
Q4 2022

Feb 10, 2023

BUY
$1.74 - $12.87 $560 - $4,144
322 Added 93.6%
666 $1,000
Q2 2022

Aug 10, 2022

SELL
$5.97 - $9.97 $15,820 - $26,420
-2,650 Reduced 88.51%
344 $3,000
Q1 2022

May 04, 2022

SELL
$8.44 - $12.49 $9,900 - $14,650
-1,173 Reduced 28.15%
2,994 $26,000
Q3 2021

Nov 05, 2021

BUY
$7.25 - $13.23 $4,350 - $7,938
600 Added 16.82%
4,167 $52,000
Q2 2021

Aug 02, 2021

BUY
$8.0 - $9.75 $18,800 - $22,912
2,350 Added 193.1%
3,567 $29,000
Q1 2021

May 13, 2021

SELL
$8.63 - $10.94 $138 - $175
-16 Reduced 1.3%
1,217 $11,000
Q4 2020

Feb 10, 2021

SELL
$8.3 - $13.59 $1,660 - $2,718
-200 Reduced 13.96%
1,233 $12,000
Q3 2020

Nov 12, 2020

BUY
$11.3 - $14.75 $5,650 - $7,375
500 Added 53.59%
1,433 $17,000
Q2 2020

Aug 14, 2020

BUY
$9.52 - $15.98 $142 - $239
15 Added 1.63%
933 $12,000
Q1 2020

May 18, 2020

BUY
$8.0 - $15.48 $7,344 - $14,210
918 New
918 $9,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $93M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.